Palatin Technologies (NYSEAMERICAN:PTN) Issues Quarterly Earnings Results

Palatin Technologies (NYSEAMERICAN:PTN) issued its quarterly earnings results on Monday. The company reported ($1.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.20) by $0.09, reports. The business had revenue of $0.30 million for the quarter, compared to the consensus estimate of $1.50 million.

Here are the key takeaways from Palatin Technologies’ conference call:

• Palatin is advancing three selective MC4R approaches—non-lipidated peptides, lipidated peptides, and oral small molecules—for rare obesity disorders, with the goal of improving efficacy, gastrointestinal tolerability, and hyperpigmentation versus existing therapies.
• The company is targeting a Phase I study for its lipidated peptide in the first half of calendar 2027, with data expected in the second half of 2027; the oral program is targeted for clinical entry in the second half of 2027, subject to funding. Preclinical data suggest the lipidated candidate could support once-weekly or potentially less frequent dosing.
• Fiscal 2026 collaboration and licensing revenue reached $13.2 million, including payments tied to Boehringer Ingelheim and the Altanispac sublicense. Management expects a Boehringer milestone within the next two to three quarters and continues to pursue partnerships for ulcerative colitis, ocular, and other non-core programs.
• Palatin ended fiscal 2026 with $7.5 million in cash and stated that existing funds are not sufficient to support operations for at least 12 months, creating substantial doubt about its ability to continue as a going concern. Additional equity financing, collaborations, or other capital will be required, and planned milestones depend on securing funding.
• Management expects operating expenses to increase during the first half of fiscal 2027 as development activities accelerate, while it evaluates the lipidated and non-lipidated peptide programs in parallel before potentially prioritizing one for later-stage development.

Palatin Technologies Trading Down 5.1%

Shares of NYSEAMERICAN:PTN opened at $9.58 on Tuesday. Palatin Technologies has a twelve month low of $5.61 and a twelve month high of $31.00. The firm’s 50 day moving average price is $9.90 and its 200-day moving average price is $13.91.

About Palatin Technologies

Palatin Technologies, Inc is a biopharmaceutical company focused on developing medicines that target melanocortin receptors, a group of receptors involved in regulating sexual function, inflammation, metabolism and other biological processes. The company’s approach uses synthetic peptide therapeutics designed to selectively activate or modulate these receptors.

Palatin’s most advanced product is Vyleesi (bremelanotide), an injectable melanocortin receptor agonist approved in the United States for the treatment of acquired, generalized hypoactive sexual desire disorder in premenopausal women.